UniQure announced plans to submit its gene therapy for Huntington's disease to the FDA for approval in Q3, following a recent FDA meeting that supported accelerated approval based on a three-year Phase 1/2 study. This marks a reversal from earlier FDA criticism under former Commissioner Marty Makary, who had questioned the trial data and demanded a placebo-controlled study. UniQure's therapy, which slows disease progression by 75%, was previously challenged due to ethical concerns about sham brain surgery controls. The FDA now agrees to an accelerated approval pathway with a commitment from UniQure to conduct a follow-up study comparing the therapy to standard care. Shares surged 70% on the news, highlighting renewed investor confidence.
Pepeto's presale raised $10.29 million rapidly, signaling strong investor interest before its major exchange listing. This surge contrasts with Cardano (ADA), which remains near six-year lows around $0.17 despite recent catalyst events like Hoskinson...
Pepeto, a new Ethereum-based cryptocurrency, has confirmed progress on its DeFi tools and surpassed $10.28 million in its presale. The project draws comparisons to Dogecoin's early success but offers working products including a DeFi exchange and cro...
LAB token fell 21.6% to $12.09 with trading volume down 23%, following a failed breakout above $17.78 resistance. Binance data shows 71% of top traders short on LAB, signaling bearish sentiment despite positive funding rates indicating some bullish b...
Strategy, led by Michael Saylor, expanded its bitcoin reserves to 846,842 BTC following the 2022 crypto market downturn that saw bitcoin prices fall below $16,000. The company raised over $60 billion in capital, acquiring more than 716,000 BTC, and n...
XRP has formed a death cross on its hourly chart as the 50-hour moving average fell below the 200-hour moving average, signaling increased selling pressure. The price has declined from a recent high of $1.29 to a low near $1.11, struggling to break a...
